

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CSPC PHARMACEUTICAL GROUP LIMITED**

### **石藥集團有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock code: 1093)**

### **VOLUNTARY ANNOUNCEMENT**

#### **“LACOSAMIDE TABLETS” OBTAINS DRUG REGISTRATION APPROVAL**

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the “Lacosamide Tablets (100 mg)” (the “**Product**”) developed by CSPC Ouyi Pharmaceutical Co., Ltd.\* (石藥集團歐意藥業有限公司), a subsidiary of the Company, has obtained drug registration approval granted by the National Medical Products Administration of the People’s Republic of China, and is deemed to have passed the consistency of quality and efficacy evaluation of generic drugs.

Lacosamide selectively enhances the slow inactivation of sodium channels. The prolonged inactivation of sodium channels reduces the inward flow of sodium ions and lowers the excitability of neurons more effectively. It is used as monotherapy and combination therapy for partial-onset seizures in patients with epilepsy aged 4 years and older. As an antiepileptic drug, lacosamide has few side effects, does not undergo hepatic metabolism and has no clinically significant interactions with other antiepileptic drugs. Owing to its unique mechanism of action, lacosamide provides a novel treatment option for partial-onset seizures in patients with epilepsy.

The approval of the Product further enriches the Group’s product portfolio for nervous system diseases.

By order of the Board  
**CSPC Pharmaceutical Group Limited**  
**CAI Dongchen**  
*Chairman*

Hong Kong, 31 May 2021

*As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan and Mr. LAW Cheuk Kin Stephen as independent non-executive directors.*

\* *For identification purposes only*